Standout Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma 2009 2026 2014 2020 6.2k
  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (2009)
    Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine
  2. Lung cancer: current therapies and new targeted treatments (2016)
    Fred R. Hirsch, Giorgio V. Scagliotti et al. The Lancet
  3. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2016)
    Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine
  4. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer (2014)
    Benjamin Solomon, Tony Mok et al. New England Journal of Medicine
  5. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial (2014)
    Yi‐Long Wu, Caicun Zhou et al. The Lancet Oncology
  6. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) (2011)
    Masahiro Fukuoka, Yi‐Long Wu et al. Journal of Clinical Oncology
  7. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008)
    Edward S. Kim, Vera Hirsh et al. The Lancet
  8. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial (2017)
    Yi‐Long Wu, Ying Cheng et al. The Lancet Oncology
  9. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study (2009)
    Tudor–Eliade Ciuleanu, Thomas Brodowicz et al. The Lancet
  10. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma (2016)
    Zhong‐Yi Dong, Wen‐Zhao Zhong et al. Clinical Cancer Research
  11. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 (2015)
    James Chih‐Hsin Yang, Lecia V. Sequist et al. The Lancet Oncology
  12. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2015)
    Ramón Rami–Porta, Vanessa Bolejack et al. Journal of Thoracic Oncology
  13. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) (2013)
    Simon Dearden, James Stevens et al. Annals of Oncology
  14. The International Association for the Study of Lung Cancer Lung Cancer Staging Project (2015)
    Hisao Asamura, Kari Chansky et al. Journal of Thoracic Oncology
  15. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer (2016)
    Martin Reck, Alexander Luft et al. Journal of Clinical Oncology
  16. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy (2015)
    Tony Mok, Yi‐Long Wu et al. Clinical Cancer Research
  17. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin (2018)
    Jing Du, Tongtong Wang et al. Free Radical Biology and Medicine
  18. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3) (2018)
    Yi‐Long Wu, Myung‐Ju Ahn et al. Journal of Clinical Oncology
  19. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations (2018)
    Tony Mok, Ying Cheng et al. Journal of Clinical Oncology
  20. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer (2018)
    Benjamin Solomon, Dong‐Wan Kim et al. Journal of Clinical Oncology
  21. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial (2019)
    Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology
  22. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC (2023)
    Masahiro Tsuboi, Roy S. Herbst et al. New England Journal of Medicine
  23. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study (2022)
    Gilberto de Castro, Iveta Kudaba et al. Journal of Clinical Oncology
  24. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study (2022)
    Benjamin Solomon, Todd M. Bauer et al. The Lancet Respiratory Medicine
  25. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma (2022)
    Lei Yang, Song Dong et al. Journal for ImmunoTherapy of Cancer
  26. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study (2024)
    Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology
  27. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study (2023)
    Hanmin Wang, Junwei Su et al. Cell Reports Medicine
  28. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial (2023)
    Juliann Chmielecki, Tony Mok et al. Nature Communications

Immediate Impact

4 by Nobel laureates 11 from Science/Nature 210 standout
Sub-graph 1 of 17

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
30 intermediate papers

Works of Yi‐Long Wu being referenced

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
2017
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
2016 Standout
and 18 more

Author Peers

Author Last Decade Papers Cites
Yi‐Long Wu 34177 28203 9906 12328 1.0k 44.6k
Vincent A. Miller 30167 29326 10353 15829 476 44.8k
Tony Mok 38626 34880 12185 15477 671 55.0k
Tetsuya Mitsudomi 22217 17840 8353 14384 530 35.9k
Frances A. Shepherd 32265 30783 7188 11958 662 48.5k
Myung‐Ju Ahn 21982 21786 5021 7271 708 31.1k
Kazuhiko Nakagawa 20348 21732 4358 9723 810 31.6k
Giuseppe Giaccone 20441 24196 6412 16575 754 45.7k
Pasi A. Jänne 39885 35323 13408 25164 645 60.0k
Marc Ladanyi 34881 23968 12927 21682 611 55.8k
Yasushi Yatabe 14927 14366 8535 11845 632 31.1k

All Works

Loading papers...

Rankless by CCL
2026